Journals / The Anatolian Journal of Cardiology / 2022 / Cilt: 26 - Sayı: 7

Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation: A Systematic Review and Meta-analysis

Pages
505–519
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Transcatheter tricuspid valve replacement could be an emerging treatment option for patients with severe tricuspid regurgitation who are not eligible for transcath- eter repair or surgical replacement because of high surgical risk and poor prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The present data aim to evaluate the feasibility of the orthotopic trans- catheter tricuspid valve replacement devices, echocardiographic, functional improve- ments, and mortality rates following replacement in patients with significant tricuspid valve regurgitation.
📊
Key Findings & Data:Methods: We systematically searched for the studies evaluating the efficacy and safety of transcatheter tricuspid valve replacement for significant tricuspid valve regurgitation.
💡
Conclusion & Impact:Conclusion: Transcatheter tricuspid valve replacement could be an emerging treatment option for patients with severe tricuspid regurgitation who are not eligible for transcath- eter repair or surgical replacement because of high surgical risk and poor prognosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: The present data aim to evaluate the feasibility of the orthotopic trans- catheter tricuspid valve replacement devices, echocardiographic, functional improve- ments, and mortality rates following replacement in patients with significant tricuspid valve regurgitation. Methods: We systematically searched for the studies evaluating the efficacy and safety of transcatheter tricuspid valve replacement for significant tricuspid valve regurgitation. The efficacy and safety outcomes were the improvements in New York Heart Association functional class, 6-minute walking distance, all-cause death, and periprocedural and long-term complications. In addition, a random-effect meta-analysis was performed comparing outcomes before and after transcatheter tricuspid valve replacement. Results: Nine studies with 321 patients were included. The mean age was 75.8 years, and the mean European System for Cardiac Operative Risk Evaluation II score was 8.2% (95% CI: 6.1 to 10.3). Severe, massive, and torrential tricuspid valve regurgitation was diagnosed in 95% of patients (95% CI: 89% to 98%), and 83% (95% CI: 73% to 90%) of patients were in New York Heart Association functional class III or IV. At a weighted mean follow-up of 122 days, New York Heart Association functional class (risk ratio = 0.20; 95% CI: 0.11 to 0.35; P 30-day mortality than predicted operative mortality (risk ratio = 1.03; 95% CI: 0.41 to 2.59; P = .95, risk ratio = 1.39; 95% CI: 0.69 to 2.81; P = .35, respectively). Conclusion: Transcatheter tricuspid valve replacement could be an emerging treatment option for patients with severe tricuspid regurgitation who are not eligible for transcath- eter repair or surgical replacement because of high surgical risk and poor prognosis.

🔖

Cite This Article

Buğan, B., Çekirdekçi, E. İ., Onar, L. Ç., Barçın, C. (2022). Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation: A Systematic Review and Meta-analysis. The Anatolian Journal of Cardiology, Cilt: 26 - Sayı: 7, 505–519. https://ajindex.com/articles/597196

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;60(4):727-800
  2. Asmarats L, Puri R, Latib A, Navia JL, Rodés-Cabau J. Tran- scatheter Tricuspid Valve Interventions: Landscape, Chal- lenges, and Future Directions. J Am Coll Cardiol. 2018;71(25):2935-2956
  3. Höke U, Auger D, Thijssen J, et al. Significant lead-induced tri- cuspid regurgitation is associated with poor prognosis at long- term follow-up. Heart. 2014;100(12):960-968. [CrossRef] 4. Anvardeen K, Rao R, Hazra S, et al. Prevalence and significance of tricuspid regurgitation post-endocardial lead placement. JACC Cardiovasc Imaging. 2019;12(3):562-564. [CrossRef] 5. Taramasso M, Gavazzoni M, Pozzoli A, et al. Tricuspid regurgita- tion: predicting the need for intervention, procedural success, and recurrence of disease. JACC Cardiovasc Imaging. 2019; 12(4):605-621. [CrossRef] 6. Goldberg YH, Ho E, Chau M, Latib A. Update on Transcatheter Tricuspid Valve Replacement Therapies. Front Cardiovasc Med. 2021;8: 619558
  4. Rahgozar K, Ho E, Goldberg Y, Chau M, Latib A. Transcatheter tricuspid valve repair and replacement: a landscape review of current techniques and devices for the treatment of tricuspid valve regurgitation. Expert Rev Cardiovasc Ther. 2021;19(5): 399-411
  5. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan— a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. [CrossRef] 9. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of obser- vational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. [CrossRef] 10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology. 2021;134:178-189. [CrossRef] 11. Sterne JA, Hernán MA, Reeves BC, et al. Robins-I: a tool for assessing risk of bias in non-randomised studies of interven- tions. BMJ. 2016;355:i4919. [CrossRef] 12. [CrossRef] 13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188
  6. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile